Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases
Sign Up to like & getrecommendations! Published in 2018 at "Digestive Diseases and Sciences"
DOI: 10.1007/s10620-018-5039-y
Abstract: In the past decades, biological agents (engineered monoclonal antibodies [mAbs]) have emerged as essential therapy for moderate-to-severe inflammatory bowel disease (IBD). More recently, the mAb tumor necrosis factor-α antagonists (anti-TNFα), infliximab, adalimumab, golimumab, and certolizumab… read more here.
Keywords: bowel; vedolizumab; response; treatment ... See more keywords
Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab
Sign Up to like & getrecommendations! Published in 2021 at "Digestive Diseases and Sciences"
DOI: 10.1007/s10620-021-06852-3
Abstract: A 27-year-old female with a history of hypertension was diagnosed with pan-ulcerative colitis (UC) after experiencing several weeks of diarrhea, hematochezia, and abdominal cramping. She was initially treated with 5-ASA and azathioprine, both of which… read more here.
Keywords: vedolizumab; infliximab; colitis; ulcerative colitis ... See more keywords
Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis
Sign Up to like & getrecommendations! Published in 2019 at "Drug Safety"
DOI: 10.1007/s40264-018-00783-1
Abstract: Vedolizumab, a humanized monoclonal antibody to the α4β7 integrin, reduces lymphocyte trafficking to the intestine. This gut-selective mechanism of action offers a safer alternative to other biologics used to treat ulcerative colitis (UC) and Crohn’s… read more here.
Keywords: vedolizumab; ulcerative colitis; disease; crohn disease ... See more keywords
Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2022.2095668
Abstract: Abstract Introduction There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails. Methods We retrieved the full datasets of two observational, multicentre,… read more here.
Keywords: vedolizumab; ulcerative colitis; clinical remission; vedolizumab ustekinumab ... See more keywords
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2023.2185510
Abstract: ABSTRACT Background Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn’s disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ. Research design and methods Mayo… read more here.
Keywords: clinical remission; vedolizumab; crohn disease; ulcerative colitis ... See more keywords
DOP49 Effectiveness and safety of vedolizumab in a matched cohort of elderly and young Inflammatory Bowel Disease patients - LIVE Study-Group
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab073.088
Abstract: Vedolizumab is the first biologic tested for the treatment of elderly patients with moderate-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD) in the GEMINI program. However, little real-life data have been reported on its… read more here.
Keywords: group; vedolizumab; elderly patients; disease ... See more keywords
P347 Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.471
Abstract: Data regarding the efficacy and safety of vedolizumab as the first line of biologic therapy for elderly patients with ulcerative colitis (UC) and Crohn’s disease (CD) or patients with contraindications against anti-tumor necrosis factor antagonists… read more here.
Keywords: contraindications anti; vedolizumab; elderly patients; clinical remission ... See more keywords
P406 A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countries
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.530
Abstract: Vedolizumab is an α4β7 integrin monoclonal antibody indicated for moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC). There are limited data on how vedolizumab impacts extraintestinal manifestations (EIM) in inflammatory bowel disease… read more here.
Keywords: inflammatory bowel; ibd; eim; vedolizumab ... See more keywords
P491 Infectious risk of vedolizumab compared with other biological agents in the treatment of Inflammatory Bowel Disease
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.614
Abstract: Vedolizumab (VDZ) is a gut selective anti-α 4β 7 integrin antibody for the treatment of Inflammatory Bowel Disease with a well-known optimal safety profile. We aimed to compare the risk of infections of VDZ with that of… read more here.
Keywords: vedolizumab; treatment inflammatory; risk; rate ... See more keywords
P477 Italian real-life study evaluating the long-term effectiveness of vedolizumab for the treatment of inflammatory bowel disease: the elderly cohort
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjz203.606
Abstract: Vedolizumab (VDZ) is the first biological therapy for Inflammatory Bowel Disease (IBD) tested, in pivotal trials, on patients up to 80 years old and has usually been presented as a safer choice in frail patients.… read more here.
Keywords: vedolizumab; bowel disease; inflammatory bowel; disease ... See more keywords
Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis.
Sign Up to like & getrecommendations! Published in 2021 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izab063
Abstract: BACKGROUND Vedolizumab is a widely used and safe therapy in inflammatory bowel disease, particularly in ulcerative colitis (UC), making it a promising candidate for enhanced efficacy by combining it with additional immunomodulatory medications. In this… read more here.
Keywords: combination; vedolizumab; treatment; combination vedolizumab ... See more keywords